{"id":"NCT00775528","sponsor":"Solvay Pharmaceuticals","briefTitle":"Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis","officialTitle":"An Open Label, Multi-center, Study to Assess the Safety and Tolerability of Pancrelipase Delayed Release Capsules in Infants and Children Less Than 7 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2009-06","completion":"2009-06","firstPosted":"2008-10-20","resultsPosted":"2010-10-01","lastUpdate":"2010-11-08"},"enrollment":19,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis","Pancreatic Exocrine Insufficiency"],"interventions":[{"type":"DRUG","name":"Pancrelipase Delayed Release","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"}],"summary":"This study will assess the safety and tolerability of pancrelipase delayed release capsules in subjects up to 6 years of age with Pancreatic Exocrine Insufficiency (PEI) due to Cystic Fibrosis.","primaryOutcome":{"measure":"Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE)","timeFrame":"10 Days","effectByArm":[{"arm":"Pancrelipase Delayed-Release Capsules","deltaMin":9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":["20441244"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Otitis media","Cough","Diarrhoea","Vomiting","Pyrexia"]}}